Presbyopia is a common variant of farsightedness affecting over 128 million people in the US, including the majority of ...

Vizz is the first and only aceclidine-based eye drop to improve near vision in adults with presbyopia. Vizz contracts the ...

The first aceclidine-based eye drop to improve near vision in adults with presbyopia, which affects more than 100 million ...

Known as Vizz, the once-daily eye drops treat age-related blurry near vision — also known as presbyopia — for up to 10 hours at a time.

The FDA has approved VIZZ eye drops (LENZ Therapeutics, Inc.) for the treatment of presbyopia, the gradual loss of near ...

The Food and Drug Administration has approved the first aceclidine-based eye drop designed to improve near vision in adults ...

Aceclidine is a cholinergic muscarinic agonist that causes contraction of the iris sphincter muscle, thereby creating a pinhole effect that extends focus depth to improve vision in presbyopia.

Vizz (Lenz Therapeutics) is the first and only aceclidine-based eye drop for presbyopia and is also the first daily solution ...

LENZ Therapeutics ( (LENZ) ) has shared an announcement. On July 31, 2025, LENZ Therapeutics announced the FDA approval of VIZZ, an aceclidine-based eye drop for treating presbyopia in adults, ...

Lenz Therapeutics has earned the FDA’s go-ahead for its aceclidine eye drop to crack the large presbyopia market, where past ...

The FDA has approved VIZZ, a once-daily, preservative-free eye drop that improves near vision in adults with presbyopia for up to 10 hours.

LENZ Therapeutics announced that FDA approved Presbyopia treatment Vizz making it the first and only aceclidine-based eye drop to be granted approval by the FDA, with samples estimated to reach the ...